Literature DB >> 6882489

Natural killing activity in Sjögren's syndrome. An analysis of defective mechanisms.

N Miyasaka, W Seaman, A Bakshi, B Sauvezie, V Strand, R Pope, N Talal.   

Abstract

Natural killing (NK) by peripheral blood mononuclear cells (PBMC) against K562 cells was examined in 27 patients with Sjögren's syndrome and 17 normal controls. NK activity in the patients was significantly reduced compared with normal controls (34.6 +/- 3.4% versus 52.2 +/- 3.4%, P less than 0.001). Patients with secondary Sjögren's had lower cytotoxicity compared with those who had primary Sjögren's (28.5 +/- 5.5% versus 37.3 +/- 4.2%, P less than 0.01). The proportion of PBMC with characteristics of NK cells was not decreased in the patients. NK by normal PBMC was diminished both in the presence of sera from patients with reduced NK and when the effector cells were pretreated with the sera. Pretreatment of target K562 cells did not alter NK activity. Suppression of NK by sera from patients did not correlate with levels of immune complexes or with antilymphocyte antibodies. Some patients had adherent cells which inhibited NK function. Addition of either indomethacin or catalase partially restored NK activity in such patients, indicating that both prostaglandins and hydrogen peroxide play a role in suppression. These data suggest that multiple mechanisms are involved in the defective NK activity seen in patients with Sjögren's syndrome. The reduction of NK activity in Sjögren's syndrome may contribute to the increased incidence of lymphoid malignancy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6882489     DOI: 10.1002/art.1780260803

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  7 in total

1.  Scleritis and multiple systemic autoimmune manifestations in chronic natural killer cell lymphocytosis associated with elevated TCRalpha/beta+CD3+CD4-CD8- double-negative T cells.

Authors:  S Yeh; Z Li; H N Sen; W-K Lim; F Gill; K Perkins; V K Rao; R B Nussenblatt
Journal:  Br J Ophthalmol       Date:  2010-06       Impact factor: 4.638

2.  Impaired release of natural killer cytotoxic factor in patients with primary Sjögren's syndrome.

Authors:  B K Pedersen; P Oxholm
Journal:  Clin Exp Immunol       Date:  1988-05       Impact factor: 4.330

3.  Bronchoalveolar lavage in rheumatoid arthritis and secondary Sjögren's syndrome.

Authors:  W Popp; L Ritschka; O Scherak; O Braun; G Kolarz; H Rauscher; H Zwick
Journal:  Lung       Date:  1990       Impact factor: 2.584

4.  Association of serum IgM kappa monoclonicity in patients with Sjögren's syndrome with an increased proportion of kappa positive plasma cells infiltrating the labial minor salivary glands.

Authors:  H M Moutsopoulos; A G Tzioufas; M K Bai; N M Papadopoulos; C S Papadimitriou
Journal:  Ann Rheum Dis       Date:  1990-11       Impact factor: 19.103

5.  Interleukin 2 defect in the peripheral blood and the lung in patients with Sjögren's syndrome.

Authors:  N Miyasaka; N Murota; K Yamaoka; K Sato; T Yamada; T Nishido; M Okuda
Journal:  Clin Exp Immunol       Date:  1986-09       Impact factor: 4.330

6.  Interleukin 2 augmentation of the defective natural killer cell activity in patients with primary Sjögren's syndrome.

Authors:  B K Pedersen; P Oxholm; R Manthorpe; V Andersen
Journal:  Clin Exp Immunol       Date:  1986-01       Impact factor: 4.330

7.  NKp30 Receptor Upregulation in Salivary Glands of Sjögren's Syndrome Characterizes Ectopic Lymphoid Structures and Is Restricted by Rituximab Treatment.

Authors:  Elena Pontarini; Elisabetta Sciacca; Sofia Grigoriadou; Felice Rivellese; Davide Lucchesi; Liliane Fossati-Jimack; Rachel Coleby; Farzana Chowdhury; Francesca Calcaterra; Anwar Tappuni; Myles J Lewis; Martina Fabris; Luca Quartuccio; Silvia Della Bella; Simon Bowman; Costantino Pitzalis; Domenico Mavilio; Salvatore De Vita; Michele Bombardieri
Journal:  Front Immunol       Date:  2021-09-14       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.